A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population

被引:65
作者
Qu, Yuanyuan [1 ,2 ,3 ]
Feng, Jinwen [1 ,2 ]
Wu, Xiaohui [1 ,2 ]
Bai, Lin [1 ,2 ]
Xu, Wenhao [1 ,2 ,3 ]
Zhu, Lingli [1 ,2 ]
Liu, Yang [1 ,2 ]
Xu, Fujiang [1 ,2 ]
Zhang, Xuan [1 ,2 ]
Yang, Guojian [1 ,2 ]
Lv, Jiacheng [1 ,2 ]
Chen, Xiuping [1 ,2 ]
Shi, Guo-Hai [1 ,2 ,3 ]
Wang, Hong-Kai [1 ,2 ,3 ]
Cao, Da-Long [1 ,2 ,3 ]
Xiang, Hang [1 ,2 ]
Li, Lingling [1 ,2 ]
Tan, Subei [1 ,2 ]
Gan, Hua-Lei [3 ,4 ,5 ]
Sun, Meng-Hong [3 ,4 ,5 ]
Qiu, Jiange [6 ]
Zhang, Hailiang [1 ,2 ,3 ]
Zhao, Jian-Yuan [1 ,2 ,7 ]
Ye, Dingwei [1 ,2 ,3 ]
Ding, Chen [1 ,2 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr,Inst Biomed Sci, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci,Dept Urol,State Key Lab Genet Engn, Shanghai, Peoples R China
[2] Fudan Univ, Human Phenome Inst, Shanghai, Peoples R China
[3] Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[4] Fudan Univ, Tissue Bank, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China
[6] Zhengzhou Univ, Acad Med Sci, Cell Signaling & Prote Res Ctr, Zhengzhou, Peoples R China
[7] Shanghai Jiao Tong Univ, Xinhua Hosp, Inst Dev & Regenerat Cardiovasc Med,Sch Med, MOE Shanghai Key Lab Childrens Environm Hlth, Shanghai, Peoples R China
基金
上海市自然科学基金; 中国博士后科学基金; 国家重点研发计划; 中国国家自然科学基金;
关键词
NICOTINAMIDE N-METHYLTRANSFERASE; SOMATIC MUTATIONS; CLASS DISCOVERY; CANCER; EXPRESSION; GENE; BIOMARKER; SURVIVAL; REVEALS; TOOL;
D O I
10.1038/s41467-022-29577-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clear cell renal cell carcinoma is an aggressive form of renal cancer, with differences in genomic mutations reported between Western and Eastern populations. In this study, the authors have compiled proteogenomic analysis of Chinese ccRCC to reveal genomic alterations and dysregulation of immune and metabolic responses. Clear cell renal cell carcinoma (ccRCC) is a common and aggressive subtype of renal cancer. Here we conduct a comprehensive proteogenomic analysis of 232 tumor and adjacent non-tumor tissue pairs from Chinese ccRCC patients. By comparing with tumor adjacent tissues, we find that ccRCC shows extensive metabolic dysregulation and an enhanced immune response. Molecular subtyping classifies ccRCC tumors into three subtypes (GP1-3), among which the most aggressive GP1 exhibits the strongest immune phenotype, increased metastasis, and metabolic imbalance, linking the multi-omics-derived phenotypes to clinical outcomes of ccRCC. Nicotinamide N-methyltransferase (NNMT), a one-carbon metabolic enzyme, is identified as a potential marker of ccRCC and a drug target for GP1. We demonstrate that NNMT induces DNA-dependent protein kinase catalytic subunit (DNA-PKcs) homocysteinylation, increases DNA repair, and promotes ccRCC tumor growth. This study provides insights into the biological underpinnings and prognosis assessment of ccRCC, revealing targetable metabolic vulnerabilities.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] Tyrosine kinase expression profile in clear cell renal cell carcinoma
    Behbahani, Turang E.
    Thierse, Claudia
    Baumann, Claudia
    Holl, Daniel
    Bastian, Patrick J.
    von Ruecker, Alexander
    Mueller, Stefan C.
    Ellinger, Joerg
    Hauser, Stefan
    WORLD JOURNAL OF UROLOGY, 2012, 30 (04) : 559 - 565
  • [22] IgG is involved in the migration and invasion of clear cell renal cell carcinoma
    Sheng, Zhengzuo
    Liu, Yang
    Qin, Caipeng
    Liu, Zhenhua
    Yuan, Yeqing
    Hu, FengZhan
    Du, Yiqing
    Yin, Huaqi
    Qiu, Xiaoyan
    Xu, Tao
    JOURNAL OF CLINICAL PATHOLOGY, 2016, 69 (06) : 497 - 504
  • [23] Targeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma
    Kowalewski, Adam
    Zdrenka, Marek
    Grzanka, Dariusz
    Szylberg, Lukasz
    CANCERS, 2020, 12 (11) : 1 - 13
  • [24] TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma
    Wu, Ping
    Xiang, Tingting
    Wang, Jing
    Lv, Run
    Wu, Guangzhen
    FEBS OPEN BIO, 2020, 10 (12): : 2588 - 2604
  • [25] Metabolic reprogramming of clear cell renal cell carcinoma
    Zhu, Haiyan
    Wang, Xin
    Lu, Shihao
    Ou, Kongbo
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [26] Clear cell papillary renal cell carcinoma: a review
    Kuroda, Naoto
    Ohe, Chisato
    Kawakami, Fumi
    Mikami, Shuji
    Furuya, Mitsuko
    Matsuura, Keiko
    Moriyama, Masatsugu
    Nagashima, Yoji
    Zhou, Ming
    Petersson, Fredrik
    Lopez, Jose I.
    Hes, Ondrej
    Michal, Michal
    Amin, Mahul B.
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (11): : 7312 - 7318
  • [27] An Overview of Epigenetics in Clear Cell Renal Cell Carcinoma
    Grammatikaki, Stamatiki
    Katifelis, Hector
    Farooqi, Ammad Ahmad
    Stravodimos, Konstantinos
    Karamouzis, Michalis V.
    Souliotis, Kyriakos
    Varvaras, Dimitrios
    Gazouli, Maria
    IN VIVO, 2023, 37 (01): : 1 - 10
  • [28] IKBKB expression in clear cell renal cell carcinoma is associated with tumor grade and patient outcomes
    Krazinski, Bartlomiej E.
    Kowalczyk, Anna E.
    Sliwinska-Jewsiewicka, Agnieszka
    Grzegrzolka, Jedrzej
    Godlewski, Janusz
    Kwiatkowski, Przemyslaw
    Dziegiel, Piotr
    Kmiec, Zbigniew
    Kiewisz, Jolanta
    ONCOLOGY REPORTS, 2019, 41 (02) : 1189 - 1197
  • [29] Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma Combined Morphologic, Immunohistochemical, and Cytogenetic Analysis
    Williamson, Sean R.
    Gupta, Nilesh S.
    Eble, John N.
    Rogers, Craig G.
    Michalowski, Susan
    Zhang, Shaobo
    Wang, Mingsheng
    Grignon, David J.
    Cheng, Liang
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (11) : 1502 - 1510
  • [30] Prognostic Value of Tumor-Associated Macrophages in Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
    Shen, Haixiang
    Liu, Jin
    Chen, Shiming
    Ma, Xueyou
    Ying, Yufan
    Li, Jiangfeng
    Wang, Weiyu
    Wang, Xiao
    Xie, Liping
    FRONTIERS IN ONCOLOGY, 2021, 11